secwatch.observer — SEC 8-K summary
======================================

Issuer:     Edwards Lifesciences Corp (EW)
CIK:        0001099800
Form:       8-K
Filed at:   2026-04-23T23:59:59+00:00
Accession:  0001099800-26-000021
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Edwards Q1 sales +16.7% to $1.65B; raises FY guidance on TAVR strength
----------------------------------------------------------------------

- Q1 sales $1.65B, +16.7% YoY; constant currency +12.7%; TAVR sales $1.20B, +14.4%.
- GAAP EPS $0.66; adjusted EPS $0.78, beating consensus; gross margin 78.0%.
- Raises FY 2026 constant currency sales growth guidance to 9-11% (from 8-10%); new TAVR growth 7-9%.
- Raises FY adjusted EPS guidance to $2.95-$3.05 from $2.90-$3.05; sees Q2 sales $1.66-$1.74B.
- Completed $500M ASR; $1.5B remaining buyback authorization; cash $2.4B, debt $0.6B.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1099800/000109980026000021/0001099800-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1099800/000109980026000021/ew-20260423.htm
  HTML page:      https://secwatch.observer/filing/0001099800-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer